Nanoparticle Filtration in a RTM Processed Epoxy/Carbon Fiber Composite

Several epoxy matrix composite panels were fabricated by resin transfer molding (RTM) E862/W resin onto a triaxially braided carbon fiber pre-form. Nanoparticles including carbon nanofiber, synthetic clay, and functionalized graphite were dispersed in the E862 matrix, and the extent of particle filtration during processing was characterized. Nanoparticle dispersion in the resin flashing on both the inlet and outlet edges of the panel was compared by TEM. Variation in physical properties such as Tg and moisture absorption throughout the panel were also characterized. All nanoparticle filled panels showed a decrease in Tg along the resin flow path across the panel, indicating nanoparticle filtration, however there was little change in moisture absorption. This works illustrates the need to obtain good nano-particle dispersion in the matrix resin to prevent particle agglomeration and hence particle filtration in the resultant polymer matrix composites (PMC)

A Strategic Vision for Telemedicine and Medical Informatics in Space Flight

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/63255/1/15305620050503924.pd

MitoNeoD:a mitochondria-targeted superoxide probe

Mitochondrial superoxide (O2⋅−) underlies much oxidative damage and redox signaling. Fluorescent probes can detect O2⋅−, but are of limited applicability in vivo, while in cells their usefulness is constrained by side reactions and DNA intercalation. To overcome these limitations, we developed a dual-purpose mitochondrial O2⋅− probe, MitoNeoD, which can assess O2⋅− changes in vivo by mass spectrometry and in vitro by fluorescence. MitoNeoD comprises a O2⋅−-sensitive reduced phenanthridinium moiety modified to prevent DNA intercalation, as well as a carbon-deuterium bond to enhance its selectivity for O2⋅− over non-specific oxidation, and a triphenylphosphonium lipophilic cation moiety leading to the rapid accumulation within mitochondria. We demonstrated that MitoNeoD was a versatile and robust probe to assess changes in mitochondrial O2⋅− from isolated mitochondria to animal models, thus offering a way to examine the many roles of mitochondrial O2⋅−production in health and disease

Simulated observation of tropospheric ozone and CO with the Tropospheric Emission Spectrometer (TES) satellite instrument

The Tropospheric Emission Spectrometer (TES) on board NASA's Aura satellite (to be launched in 2004) will provide measurements of global distributions of ozone, CO, and other key chemical species in the troposphere. In order for TES to meet a design lifetime of 5 years, it has been determined that a global survey strategy with ∼50% duty cycle must be identified. In this study, simulated concentrations of ozone and CO from the GEOS-CHEM global three-dimensional (3-D) model of troposphere chemistry are used as a time-varying synthetic atmosphere for demonstrating and assessing the capabilities of TES nadir observations. Autocorrelation analyses of the model species fields for different time lags identify a significant 1-day correlation and support a 1-day-on/1-day-off observation strategy. Three major steps are then taken to demonstrate and evaluate TES products: (1) species profiles along the TES orbit track are sampled from the model 3-D time-varying fields with cloudy scenes (50-60% of total scenes) removed; (2) nadir-retrieved profiles (“level 2 products”) are obtained from these “true” synthetic profiles using TES retrieval characteristic functions; (3) interpolated daily global maps (“level 3 products”) are generated to compare with the original model fields. The latter comparison indicates that the error in the level 3 products relative to the true fields for ozone and CO is <10% in ∼70% of cases and <20% in 80–90% of cases. The three major sources of error lie in the asynoptic orbital sampling, the retrieval, and the level 3 global mapping.Engineering and Applied Science

A sensitive mass spectrometric assay for mitochondrial CoQ pool redox state in vivo.

Coenzyme Q (CoQ) is an essential cofactor, primarily found in the mitochondrial inner membrane where it functions as an electron carrier in the respiratory chain, and as a lipophilic antioxidant. The redox state of the CoQ pool is the ratio of its oxidised (ubiquinone) and reduced (ubiquinol) forms, and is a key indicator of mitochondrial bioenergetic and antioxidant status. However, the role of CoQ redox state in vivo is poorly understood, because determining its value is technically challenging due to redox changes during isolation, extraction and analysis. To address these problems, we have developed a sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay that enables us to extract and analyse both the CoQ redox state and the magnitude of the CoQ pool with negligible changes to redox state from small amounts of tissue. This will enable the physiological and pathophysiological roles of the CoQ redox state to be investigated in vivo

A sensitive mass spectrometric assay for mitochondrial CoQ pool redox state in vivo

Coenzyme Q (CoQ) is an essential cofactor, primarily found in the mitochondrial inner membrane where it functions as an electron carrier in the respiratory chain, and a lipophilic antioxidant. The redox state of the CoQ pool is the ratio of its oxidised (ubiquinone) and reduced (ubiquinol) forms, and is a key indicator of mitochondrial bioenergetic and antioxidant status. However, the role of CoQ redox state in vivo is poorly understood, because determining its value is technically challenging due to redox changes during isolation, extraction and analysis. To address these problems, we have developed a sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay that enables us to extract and analyse both the CoQ redox state and the magnitude of the CoQ pool with negligible changes to redox state from small amounts of tissue. This will enable the physiological and pathophysiological roles of the CoQ redox state to be investigated in vivo

Myopia Outcome Study of Atropine in Children (MOSAIC): an investigator-led, double-masked, placebo-controlled, randomised clinical trial protocol

Background: The Myopia Outcome Study of Atropine in Children (MOSAIC) aims to explore the efficacy, safety, acceptability and mechanisms of action of 0.01% unpreserved atropine for myopia control in a European population. Methods: MOSAIC is an investigator-led, double-masked, placebo-controlled, randomised clinical trial (RCT) investigating the efficacy, safety and mechanisms of action of 0.01% atropine for managing progression of myopia. During Phase 1 of the trial, 250 children aged 6-16 years with progressive myopia instil eye drops once nightly in both eyes from randomisation to month 24. From month 24 to 36 participants are re-randomised in Phase 2 of the trial, into continued 0.01% atropine, and washout, at 1:1 ratio for those participants initially randomised to the intervention arm (n=167), during which any potential rebound effects on cessation of treatment will be monitored. All participants initially assigned to the placebo (n=83) crossover to the intervention arm of the study for Phase 2, and from month 24 to 36, instil 0.01% atropine eye drops in both eyes once nightly. Further treatment and monitoring beyond 36 months is planned (Phase 3) and will be designed dependent on the outcomes of Phase 1. Results: The primary outcome measure is cycloplegic spherical equivalent refractive error progression at 24 months. Secondary outcome measures include axial length change as well as the rebound, safety and acceptability profile of 0.01% atropine. Additional analyses will include the mechanisms of action of 0.01% atropine for myopia control. Conclusions: The generalisability of results from previous clinical trials investigating atropine for myopia control is limited by the predominantly Asian ethnicity of previous study populations. MOSAIC is the first RCT to explore the efficacy, safety and mechanisms of action of unpreserved 0.01% atropine in a predominantly White population